{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 25,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/7",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.03,
        "y": 0.769
      },
      "kind": "list",
      "text": "Phase 1b: Collaboration with ENGOT and GOG-F.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27a54a42-f540-47ca-9ad7-a0209c74a01a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.03,
        "y": 0.238
      },
      "kind": "list",
      "text": "Precision Medicine Approach: Discovered at ICR, GCN2 kinase activator, ARID1a loss as sensitivity marker.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ee05d78-f217-4c22-9bfa-9a7326cda08d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.03,
        "y": 0.592
      },
      "kind": "list",
      "text": "Preclinical & Clinical Data: Tumor growth inhibition, ESMO/AACR presentations, Phase 1a PK/PD data.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5d05b20-a97a-4e45-9959-0a83ac9215cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.03,
        "y": 0.415
      },
      "kind": "list",
      "text": "Focused Clinical & Regulatory Strategy: Fast Track Designation for ARID1A-mutated ovarian carcinoma, Orphan Drug Designation for cholangiocarcinoma.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8dcb539-de28-4db6-a677-d6b3915aa2e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.42,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "NXP800 Key Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6eabbd38-255b-48d2-8435-44e67fd0ba83",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 4,
      "beatId": "741a2480-95f8-4104-b5a4-c93aaf29dad7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents NXP800 and NXP900 as solutions, with details on their mechanism of action and early-stage results.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
      "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
      "position": 0,
      "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}